The Marburg virus belongs to the family Filoviridae and is closely related to the Ebola virus. It causes severe and often fatal hemorrhagic fever in humans and non-human primates, with sporadic outbreaks reported in Africa. Named after the German city where the first known outbreak occurred in 1967, the Marburg virus is transmitted to humans through direct contact with infected animals or their bodily fluids. Human-to-human transmission can occur through close contact with the blood, organs, or other bodily fluids of infected individuals. The virus's incubation period ranges from 2 to 21 days, with symptoms including fever, severe headache, malaise, and, in later stages, hemorrhagic manifestations. There is no specific antiviral treatment for Marburg virus disease, and supportive care is the mainstay of management. Efforts to control Marburg virus outbreaks involve isolation of infected individuals, contact tracing, and strict infection prevention measures. Research continues to enhance our understanding of the virus, develop potential vaccines and antiviral therapies, and improve public health responses to minimize the impact of Marburg virus disease.
Submit your abstract Today
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Prophylactic and Molecular Approaches for Mitigating Human Influenza A Viruses: i. Evaluating influenza Vaccine Effectiveness in the Older population ii. Down-regulation of influenza virus genes with novel siRNA-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a Novel Multi-component Vaccine to Address the Burden of Otitis Media in High-Risk Populations
Ayesha Zahid, Griffith University, Australia
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Immunosuppression in COVID-19 Patients and Emerging Fungal Infections: Vaccines, Diagnosis and Strategies to Treat Comorbidities
K R Aneja, Kurukshetra University, India
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Why is the vaccine life-threatening if people get a fever after a COVID-19 vaccination
Yacob Mathai, Marma Health Centre, India
Title : Barriers to polio eradication in South Asia: A systematic review
Awranoos Ahadi, Bolan Medical College, Pakistan